Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.81 |
| ▸ | KDR | P35968 | 5/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.81 |
| ▸ | RET | P07949 | 4/20 | 0.81 |
| ▸ | KIT | P10721 | 4/20 | 0.81 |
| ▸ | FLT1 | P17948 | 3/20 | 0.81 |
| ▸ | FLT4 | P35916 | 3/20 | 0.81 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.81 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | STK10 | O94804 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | BCR | P11274 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.81 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.81 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21092225 | 0.91 | FGFR4 (0.84) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL29349806 | 0.90 | FGFR4 (1.00) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL864638 | 0.90 | FGFR4 (1.00) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL29372021 | 0.90 | FGFR4 (1.00) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| SCHEMBL1894845 | 0.90 | FGFR4 (0.71) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| SCHEMBL1894581 | 0.90 | KDR (0.66) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| SCHEMBL16382878 | 0.89 | FGFR4 (0.80) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| SCHEMBL1895420 | 0.89 | FGFR4 (0.83) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL1389214 | 0.89 | FGFR4 (0.98) | FGFR4FGFR1KDRPDGFRAPDGFRB | |
| SCHEMBL864110 | 0.88 | FGFR4 (0.82) | FGFR4FGFR1KDRPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-113924288-B | Quinolinyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3950677-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113924288-A | Quinolyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| WO-2020200160-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 北京国鸿生物医药科技有限公司 | 2020-10-08 | — | — | WO | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | FGFR4 682/4885FGFR1 165/4885KDR 22/4885 |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | HDAC11, HDAC1, HDAC6 | FGFR4 816/4885FGFR1 164/4885KDR 1621/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | FGFR4 1688/4885FGFR1 445/4885KDR 60/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | FGFR4 1688/4885FGFR1 445/4885KDR 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.